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Abstract Ahnak1 is a giant, ubiquitously expressed,
plasma membrane support protein whose function in skel-
etal muscle is largely unknown. Therefore, we investigated
whether ahnak would be influenced by alterations of the
sarcolemma exemplified by dysferlin mutations known to
render the sarcolemma vulnerable or by mutations in cal-
pain3, a protease known to cleave ahnak. Human muscle
biopsy specimens obtained from patients with limb girdle
muscular dystrophy (LGMD) caused by mutations in dys-
ferlin (LGMD2B) and calpain3 (LGMD2A) were investi-
gated for ahnak expression and localization. We found that
ahnak1 has lost its sarcolemmal localization in LGMD2B
but not in LGMD2A. Instead ahnak1 appeared in muscle
connective tissue surrounding the extracellular site of the
muscle fiber in both muscular dystrophies. The entire giant
ahnak1 molecule was present outside the muscle fiber and
did only partially colocalize with CD45-positive immune
cell infiltration and the extracelluar matrix proteins fibro-
nectin and collagenVI. Further, vesicles shedded in response
to Ca2? by primary human myotubes were purified and their
protein content was analysed. Ahnak1 was prominently
present in these vesicles. Electron microscopy revealed a
homogenous population of vesicles with a diameter of about
150 nm. This is the first study demonstrating vesicle release
from human myotubes that may be one mechanism under-
lying abnormally localized ahnak1. Taken together, our
results define ahnak1 in muscle connective tissue as a novel
feature of two genetically distinct muscular dystrophies that
might contribute to disease pathology.
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Introduction
Proper skeletal muscle function relies on muscle fiber
integrity, efficient muscle repair and regeneration which are
disturbed in muscular dystrophies (Goldstein and McNally
2010). Limb girdle muscular dystrophies (LGMD) comprise
clinically and genetically heterogenous disorders charac-
terized by progressive wasting of the skeletal muscle com-
bined with an increase in muscle connective tissue. LGMD
type 2B and LGMD type 2A are caused by mutations in
dysferlin (MIM*603009) and calpain3 (MIM*114240),
respectively (Bashir et al. 1998; Richard et al. 1995). Dys-
ferlin is a sarcolemmal protein involved in plasma mem-
brane repair and muscle regeneration (Bansal et al. 2003;
Chiu et al. 2009). Mutations in dysferlin lead to reduced
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expression and/or altered subcellular localization of the
protein in muscle fibers (Wenzel et al. 2006; Spuler et al.
2008; Krahn et al. 2009). Calpain3 is a cystein protease that
cleaves cytoskeletal and myofibrillar proteins and is repor-
ted to serve as gatekeeper of proper sarcomere function
(Kramerova et al. 2005; Beckmann and Spencer 2008).
Ahnak1 (desmoyokin, MIM*103390) interacts with
dysferlin and is cleaved by calpain 3 (Huang et al. 2007,
2008). Ahnak1 is a large protein implicated in plasma
membrane support (Hohaus et al. 2002; Gentil et al. 2003)
and Ca2? signaling in a variety of cells (Hashimoto et al.
1995; Haase 2007; Matza et al. 2008; Alli and Gower 2009;
Alvarez et al. 2010). Much attention has been paid to ahnak
as a marker of enlargeosomes, which are non-secretory,
cytoplasmic vesicles competent for regulated exocytosis
after rising intracellular Ca2?. Enlargeosomes mediate cell
surface enlargement and contribute to plasma membrane
repair and vesicle shedding (Borgonovo et al. 2002; Coc-
ucci et al. 2007; Lorusso et al. 2006). Little is known about
ahnak function in skeletal muscle. Recently, ahnak1 and
ahnak2 have been described as costameric proteins (Marg
et al. 2010). Furthermore, ahnak has been identified as a
constituent of the dysferlin protein complex that is
important for sarcolemmal integrity (Huang et al. 2007,
2008; de Morree et al. 2010). Interestingly, the interaction
between ahnak1 and dysferlin is lost after proteolytic
processing of ahnak1 by calpain3 (Huang et al. 2008).
Because of the complex interactions between ahnak1,
dysferlin, and calpain3 and their role in muscle repair and
regeneration we compared ahnak1 expression in patients
with LGMD2B and LGMD2A. We found an altered
expression of ahnak1 at the sarcolemma and identified
ahnak1 as a novel constituent of the endomysial compart-
ment in the two genetically distinct muscular dystrophies
studied. Furthermore, we demonstrate the release of ah-
nak1-containing vesicles from normal human myotubes
after rising intracellular Ca2?. We infer that ahnak1 release
by secreted vesicles may be one mechanism underlying
abnormally localized ahnak1 in muscular dystrophy.
Materials and methods
Patients
The Charite´ internal review board approved the study and
written informed consent was obtained from all patients.
Skeletal muscle biopsies (M. vastus lateralis) from 6 patients
with dysferlinopathy, 6 patients with calpainopathy and 6
healthy controls were analyzed. Patients with LGMD2B
were affected by different mutations in DYSF including
homozygous c.4022T [ C; homozygous c.2810 ? 2T [
A; compound heterozygous c.855 ? 1delG and
c.895G [ A; compound heterozygous c.1448C [ A and
c.*107T [ A; compound heterozygous c.5606G [ A and
c.2875C [ T (see Table 2 in (Wenzel et al. 2006)) resulting
in the complete loss or intracellular accumulation of dys-
ferlin, respectively. Patients with LGMD2A were affected
by different compound heterozygous mutations in the cal-
pain3 gene including c.550delA and c.1745 ? 5G [ C;
c.550delA and c.883_886delGATAinsCTT; c.1469G [ A
and c.1801-1G [ A; c.700G [ A and c.1324T [ C;
c.551C [ T and c.801 ? 1G resulting in the complete loss
or reduced expression of calpain3, respectively.
Antibodies against ahnak
The isoform-specific ahnak1 antibody was prepared by
immunizing rabbits with a C-terminal recombinant ahnak1
protein fragment (amino acid residues 4893-5535) as
recently described (Marg et al. 2010). In some experiments
ahnak was labeled with the KIS antibody that was raised
against the internal repeating units of ahnak (KIS-
MPDVDLHLKGPK). The KIS antibody has been charac-
terized elsewhere (Haase et al. 2004) and corresponds to
the antibody used by Huang et al. (2007, 2008). The
monoclonal antibody (M01, clone 3G7) against the N-ter-
minal part of ahnak1 was purchased from Abnova.
SDS-PAGE and Western blot analysis
Total protein fractions were extracted from frozen tissue
specimens and myotubes by homogenization with SDS-
sample buffer as previously described (Haase et al. 2004).
Exosomal proteins were dissolved in SDS-sample buffer and
heated at 95C for 5 min. Protein samples were separated by
SDS-PAGE and transferred to nitrocellulose filters overnight
at 70 mA with a Tris/glycine buffer, pH 8.3, containing 10%
methanol and 0.1% SDS in a Biorad Protean III system. The
transferred proteins were visualized by staining with Pon-
ceau-S. Membranes were further processed for immunode-
tection according to standard protocols. Briefly, they were
subsequently incubated with the affinity-purified, polyclonal
antibody against ahnak1 (1 lg IgG/ml) or monoclonal anti-
bodies against desmin (DAKO) and annexin2 (BD Labora-
tories) for 90 min and the respective secondary horseradish
peroxidase-conjugated antibodies (Pierce, Rockford, USA).
Immunoreactive protein bands were visualized by Chemi-
luminescent HRP Substrate (Millipore, USA) and Amersham
Hyperfilm (GE Healthcare, Japan).
Myoblast purification and differentiation
Biopsies were taken from M.vastus lateralis. Primary
myoblast cultures were isolated by protease digestion from
fresh muscle biopsies and expanded at 37C in humidified
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atmosphere with 5% CO2 in skeletal muscle growth med-
ium (PromoCell, Heidelberg, Germany) supplemented with
10% FCS, glutamine (3 mM) and gentamycin (40 lg/ml)
(Gibco, Paisely, UK). All cultures were enriched in myo-
blasts by immuno-magnetic cell sorting using anti-CD56/
NCAM antibody coated magnetic beads (Miltenyi Biotech,
Bergisch Gladbach, Germany). Purity of the myoblast
preparation was verified by staining with an anti-desmin
antibody (DAKO) revealing more than 95% desmin-posi-
tive cells. Differentiation of myoblasts into myotubes was
initiated at approximately 90% confluence by switching to
differentiation medium (DMEM, 2% horse serum) fol-
lowed by cultivation for 7 days.
Immunocytochemistry
Myoblasts were grown in 8 well chamber slides (Nunc,
Langenselbold, Germany) and differentiated into myotu-
bes, fixed for 10 min with 4% formaldehyde, permeabili-
zed for 15 min with 0.2%Triton X100 and blocked with
1% BSA diluted in PBS. The following primary antibodies
were used for immunostaining: mouse monoclonal anti-
bodies to MyHCs (Novocastra, Newcastle upon Tyne, UK),
dystrophin (Abcam), a-actinin and vinculin (both from
Sigma-Aldrich) and rabbit polyclonal antibodies to human
ahnak1 (3 lg IgG/ml) in combination with secondary
Alexa 488-conjugated anti-mouse IgG or Alexa 594-con-
jugated anti-rabbit IgG antibodies (Invitrogen), respec-
tively. Nuclei were counterstained with Hoechst 33258.
Images were collected with a Leica DMI6000 fluorescence
microscope.
Immunohistochemistry
Immunofluorescenct staining was performed on transversal
5 lm cryostat sections of skeletal muscle biopsies
(M.vastus lateralis) of patients with dysferlinopathy, cal-
painopathy and healthy controls. After fixation with aceton,
muscle sections were blocked with 10% goat serum in PBS
and stained with rabbit polyclonal anti-ahnak1, anti-fibro-
nectin (Abcam) or KIS antibodies in combination with
Alexa 594-conjugated anti-rabbit IgG antibodies (Invitro-
gen). Sections were double-labelled with a monoclonal
antibody to dystrophin C-terminus (Novocastra), CD45
(BD Laboratories) or ahnak1-NT (Abnova) in combination
with Alexa 488-conjugated anti-mouse IgG antibodies
(Invitrogen) to highlight the sarcolemma. Negative control
samples without primary or secondary antibodies were
included and produced negligible fluorescence. Images
were collected with a Leica DM6000 or BioRad MRC1024
microscope. To block specific interactions, rabbit poly-
clonal anti-ahnak1 antibody was preincubated with a
20-fold molar excess of the recombinant ahnak1-GST
fusion protein used for immunization (see Antibodies)
overnight at 4C and applied to cryosections as described
above. For semiquantitative analysis ahnak1 localization
was grouped into four categories after visual inspection of
sections from patients with calpainopathy, dysferlinopathy
and healthy controls: absent, partially reduced or present at
the sarcolemma and localized to the endomysium.
Vesicle purification and characterization
Secreted vesicles were isolated by differential centrifugation
from cell culture supernatants of human myotubes differ-
entiated in 10 cm diameter petri dishes. After 24 h in serum
free media the myotubes were washed with fresh medium
and then exposed, for 10 min at room temperature, to ion-
omycin (1 lM, 3.7 lM), phorbol(12-myristoyl-13-acetyl)
(0.5 lM), and ATP (1 mM) or to their solvents, diluted in
2 ml medium. At the end of the incubations, the media were
harvested and subjected to differential centrifugation at 4C
starting with 4.0009g to remove large cell remnants. The
resulting supernatants were filtered through a syringe filter
with 0.22 lm cut-off (Millipore), and the filtrates were
centrifuged at 100.0009g in an Optima ultracentrifuge
(Beckman-Coulter) for 2 h to pellet vesicles which were
only visible upon ionomycin treatment. The pellets
(*50 lg of protein/petri dish) were either resuspended for
Western blotting or were processed for negative staining and
electron microscopy. For the latter method, the preparations
were fixed in 2% freshly prepared formaldehyde in 200 mM
HEPES buffer, pH 7.4 over night. Small aliquots of this
mixture were applied to formvar-carbon-coated grids for
5 min, washed shortly with bidistilled water and stained
with 5% aqueous uranyl acetate. Images were taken with a
Zeiss 910 electron microscope equipped with a 1 k 9 1 k
high speed slow scan CCD camera and the iTEM software
(Olympus Soft Imaging Solutions, Mu¨nster, Germany).
Results
Ahnak1 is mislocalized in dysferlinopathy
and calpainopathy
To examine potential alterations in the distribution of ah-
nak1 in muscular dystrophies caused by mutations in
dysferlin and calpain3, we employed a recently character-
ized ahnak1 isoform-specific antibody (Marg et al. 2010).
Cross sections of normal human skeletal muscle revealed a
sarcolemma associated staining pattern for ahnak1 (Fig. 1,
upper panel, green) that closely merged with dystrophin
labeling (Fig. 1, upper panel, red). Next we analyzed the
distribution of ahnak1 in patients with dysferlinopathy and
calpainopathy. In muscle from a LGMD2B patient, plasma
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membrane staining with antibodies to dystrophin revealed
myopathic changes typical for dystrophic muscle, such as
pathological variations in fiber size, split fibers, and an
increase in endomysial fibrosis (Fig. 1, middle panel, red).
Ahnak1 labeling at the sarcolemma was dramatically
reduced in all six patients with dysferlinopathy, compared
to normal skeletal muscle. We show a representative
example in Fig. 1 (middle panel, green). Remarkably, we
observed strong immunostaining for ahnak1 outside the
muscle fibers in the endomysium and perimysium in dys-
ferlinopathy (arrows in Fig. 1, middle panel). Sections of
skeletal muscle from patients with calpainopathy demon-
strated strong dystrophic changes including increased
endomysial fibrosis, as revealed by sarcolemmal membrane
staining for dystrophin (Fig. 1, lower panel, red). In all six
patients with calpain3 mutations, ahnak1 was unchanged or
only slightly reduced at the sarcolemma (Fig. 1, lower
panel, green). Interestingly, merged images revealed strong
ahnak1 labeling outside the muscle fiber within the endo-
mysium in calpainopathy (arrows in Fig. 1, lower panel)
very similar to dysferlin-deficient muscle as described
above. Thus, in both these dystrophies, ahnak1 was present
outside the muscle fiber in the endomysium and formed
line structures partially ensheathing the muscle fiber
(arrows in Fig. 1, middle and lower panel). Ahnak1
localization in patients and healthy controls is summarized
in Online Resource 1. The specificity of ahnak1 immuno-
staining in normal and dystrophic muscle was verified by
blocking ahnak1 labeling with the recombinant ahnak1
protein used to generate the antibody (Online Resource 2a).
We next addressed the question whether ahnak1 frag-
ments or the full-length protein reside outside the muscle
fiber in the endomysial compartment. Double labeling of
ahnak1 with antibodies directed against either the
Fig. 1 Endomysial ahnak1 deposits surrounding the sarcolemma in
dysferlinopathy and calpainopathy. Cross-sections of human skeletal
muscle were stained for ahnak1 together with dystrophin that
highlights the sarcolemma. Confocal microscopy of normal human
skeletal muscle demonstrated sarcolemmal localization of ahnak1
(green), together with dystrophin (red; upper panel). Skeletal muscle
from an exemplary patient with dysferlinopathy (middle panel) and an
exemplary patient with calpainopathy (lower panel) revealed strong
dystrophic changes combined with increased endomysial localization
of ahnak1. Ahnak1 formed line structures outside the muscle fibers,
often parallel to the plasma membrane (arrows; bar, 25 lm)
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N-terminus or the C-terminus of the 700-kDa protein
revealed perfect colocalization for both ahnak1 epitopes in
calpain3-deficient muscle (Fig. 2a) and dysferlin-deficient
muscle (data not shown). Western blots of tissue homoge-
nates from normal and dystrophic human skeletal muscle
revealed a single immunoreactive band for ahnak1 with the
expected high molecular mass (Fig. 2b). These findings
suggest that the entire giant ahnak1 molecule is present in the
enlarged endomysium in both forms of muscular dystrophies.
Furthermore, we used the KIS antibody for ahnak label-
ing in muscle sections. This antibody was generated against
the repeating units of ahnak1 and is expected to detect both
ahnak1 and ahnak2. We observed strong, endomysial ah-
nak1/2 labeling in dysferlin-deficient and calpain3-deficient
patients (Online Resource 2b) that is consistent with a
localization of ahnak outside the muscle fiber as shown
above with the ahnak1 isoform-specific antibody.
Extracellular ahnak1 in relation to immune infiltration
and interstitial fibrosis
To shed light on the origin of endomysial ahnak1, we
considered the possibility that ahnak1 was derived from
cells invading the endomysial space such as activated
macrophages and lymphocytes, in which ahnak1 expres-
sion is well documented (Matza et al. 2008; Matza and
Flavell 2009). We thus combined ahnak1 labeling with
staining for CD45, a marker for immune cells (Fig. 3). In
healthy human skeletal muscle, infiltration of immune cells
was hardly visible. Only a single rounded cell was detected
outside the skeletal muscle fiber that was labeled for both
CD45 and ahnak1 (Fig. 3, upper panel). Dystrophic muscle
from dysferlin-deficient and calpain3-deficient patients
revealed significant CD45-positive immune cell infiltration
that partially co-localized with ahnak1 labeling. However,
ahnak1 showed a broader distribution and ahnak1-positive
line structures ensheathing the muscle fibers were not
labeled by CD45 (Fig. 3, middle and lower panel). Thus,
infiltration of immune cells was probably not the only
reason for the presence of ahnak1 in the endomysium.
To relate ahnak1 expression to interstitial fibrosis in
dystrophic muscle, we compared its localization with
fibrosis markers, namely the extracellular matrix (ECM)
proteins fibronectin and collagen VI (Alvarez et al. 2002;
Fadic et al. 2006). In healthy specimen, fibronectin was only
slightly expressed and was preferentially localized at blood
vessels between muscle fibers and in the perimysial space
(Fig. 4, upper panel). The increase in fibrosis in dystrophic
muscle was accompanied by an increase in fibronectin
expression in the endomysium in both dysferlinopathy and
calpainopathy (Fig. 4, middle and lower panel, respec-
tively). However, fibronectin and ahnak1 showed only a
partially overlapping expression pattern in the endomysium
in dystrophic muscle. Fibronectin distribution was broader
and again the characteristic ahnak1-positive structures
embracing the sarcolemma were not highlighted by fibro-
nectin (Fig. 4, middle and lower panel). Moreover, in dys-
trophic muscle ahnak1 showed a localization distinct from
the ECM molecule, collagen VI, and the basal lamina
marker, laminin a2 (Fig. 5). These findings support the
presence of ahnak1 outside the muscle fiber in dystrophic
muscle. However, ahnak1 does not entirely co-localize with
the ECM proteins fibronectin, collagen VI, and laminin a2.
May extracellular ahnak1 originate from muscle?
We tested the hypothesis whether ahnak outside the muscle
fiber may be released from muscle through secreted vesi-
cles. We employed primary human myotubes as a model
and adapted protocols for vesicle shedding (Cocucci et al.
2007; Lorusso et al. 2006). Multinucleated myotubes were
formed from normal primary human myoblasts after 7 days
Fig. 2 Ahnak1 expression analyzed with domain-specific antibodies
in dystrophic muscle. a Ahnak1 labeling in a calpainopathy patient
with anti ahnak1-NT mAb and anti ahnak1 pAb directed against the
N-terminal and C-terminal region of ahnak1, respectively. There was
a strong co-localization of the N-terminal and C-terminal parts of
ahnak1 (bar, 50 lm). b Western blots from a healthy control (lane 1)
and from a patient with calpainopathy (lane 2) showed ahnak1
migrating as a single *700 kDa protein in both samples. Protein
staining of MyHC was used as loading control
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of differentiation. At this state of maturation the myotubes
showed a striated staining pattern for myosin heavy chain
(MyHC) and a-actinin (labels Z-lines) indicative for the
formation of sarcomeres (Fig. 6). Costamere-like structures
were not yet developed. The costameric proteins vinculin
and dystrophin showed a focal adhesion-like staining
Fig. 3 Ahnak1 expression and infiltration of immune cells in
dystrophic human skeletal muscle. Cross-sections of normal human
skeletal muscle (upper panel), a patient with dysferlinopathy (middle
panel) and a patient with calpainopathy (lower panel) were labeled
for ahnak1 (green) and CD45 (red) as an immune cell marker (bar,
50 lm)
Fig. 4 Comparison of ahnak1
and fibronectin expression in
normal and dystrophic human
skeletal muscle. Cross-sections
of normal human skeletal
muscle (upper panel), an
exemplary patient with
dysferlinopathy (middle panel),
and a patient with calpainopathy
(lower panel) were labeled for
ahnak1 (anti ahnak1-NT mAb;
green) and fibronectin (red) as a
marker for endomysial fibrosis
(bar, 50 lm)
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pattern and an intracellular localization, respectively
(Fig. 6). In myotubes ahnak1 was distributed throughout
the cytoplasm and at the plasma membrane (Fig. 6). Ah-
nak1 staining was only observed after permeabilization of
cells indicating that ahnak1 is not exposed at the outer
surface of the plasma membrane (data not shown).
To evoke vesicle shedding we incubated cultured
adherent myotubes with PMA, ionomycin, ATP or vehicle
as control. Media were harvested after 10 min of drug
application and were subjected to differential centrifuga-
tion as outlined in Materials and methods. The high speed
pellet following 100.0009g centrifugation was considered
as secreted vesicles and their protein composition was ana-
lysed by Western blotting. Figure 7a clearly demonstrates
that this fraction contained ahnak1 together with annexin 2
upon treatment with the Ca2? ionophore ionomycin,
whereas the intermediate filament protein desmin was
absent. Robust release of ahnak1 into the vesicular fraction
was repeatedly seen at a concentration of 1 lM ionomycin,
while PMA (0.5 lM, Fig. 7a) and ATP (1 lM, data not
shown) failed to induce the release of any constituent into
the high speed pellet. Electron microscopy was performed
to characterize the vesicular fraction released by ionomycin
treatment. Representative images depicted in Fig. 7b
revealed that this myotube-derived preparation contained
rounded vesicles with a diameter of 150–200 nm. The
characteristics of repeated vesicle preparations are given in
Table 1. It is noteworthy to mention that an additional
Fig. 5 Comparison of collagen VI, laminin a2 and ahnak1 expression
in dystrophic human skeletal muscle. Cross-sections of human
skeletal muscle of an exemplary patient with calpainopathy (a) and
a patient with dysferlinopathy (b) were labeled for ahnak1 (red) and
collagen VI or laminin a 2 (green), as a marker for endomysial
fibrosis and basal lamina, respectively (bar, 50 lm)
Fig. 6 Differentiation state of primary human myotubes. Immuno-
fluorescence staining with either anti-MyHC or with anti-a actinin
antibody showed correct organization of the sarcomere. Costamere-
like structures were not yet developed, as shown by staining with anti-
vinculin or anti-dystrophin antibody. Ahnak1 was distributed
throughout the cytoplasm and at the plasma membrane (bar, 20 lm)
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purification step through a 0.22 lm filter did essentially not
alter the dimensions of secreted vesicles. Importantly, no
evidence of contamination with other membrane particles
or cell remnants was observed in our vesicle preparation
(Fig. 7b).
Discussion
The important finding in our study is the localization of
ahnak1 outside the muscle fiber in patients with calpain-
opathy (LGMD2A) and dysferlinopathy (LGMD2B). We
believe this information implies that ahnak1 is faultily
regulated in the muscular dystrophies we investigated.
Elucidation of the mechanisms involved in ahnak1 mislo-
calization could help explain these muscle diseases further.
Healthy human skeletal muscle did not show endomysial
ahnak1. In cross sections, we observed a densely packed,
plasma membrane associated staining pattern for ahnak1
that closely merged with dystrophin labeling. Plasma
membrane localization is in line with previous reports and
supports the functional role of ahnak in skeletal muscle as a
plasma membrane stabilizer and costamer-associated pro-
tein (Hohaus et al. 2002; Haase et al. 2004; Gentil et al.
2003; Benaud et al. 2004; Marg et al. 2010). Specifically, in
patients with LGMD2B a separation between dystrophin
and ahnak1 became apparent as ahnak1 labeling at the
muscle membrane was strongly reduced. This finding is in
agreement with Huang et al. (2007) who described a con-
certed loss of dysferlin and ahnak at the plasma membrane
in dysferlinopathy patients. Loss of ahnak from the sarco-
lemma seems to be characteristic for dysferlinopathies
because it is not observed in calpainopathies. However,
endomysial localization of ahnak1 appeared to be a com-
mon feature in both muscle diseases. In fact, we found
ahnak1 accumulation in the enlarged interstitial compart-
ment of dysferlin-deficient and calpain3-deficient muscle.
Again, co-immunostaining of ahnak1 and dystrophin
allowed clear differentiation between plasma membrane
labeling and endomysial labeling. Ahnak1 staining alone
could have been misinterpreted as sarcolemmal thickening
or multilayered basal lamina. Several antibodies against
different domains of ahnak1 including N- and C-terminus as
well as the repeating units support ahnak1 deposition out-
side the dystrophic muscle fiber. Furthermore, we corrob-
orated the localization of ahnak1 outside the muscle fibers
in the two diseases by partial co-labeling with the extra-
cellular matrix molecules fibronectin and collagen VI.
These proteins are accepted constituents of endomysial
connective tissue in the dystrophic muscle.
In general, muscular dystrophies are characterized by a
progressive muscle weakness and wasting, in combination
with fibrosis that contributes to disease severity (Alvarez
et al. 2002; Fadic et al. 2006; Goldstein and McNally
2010). Excessive accumulation of matrix components in
the endomysium may have strong effects on the activation
and differentiation of resident cells, and therefore muscle
regeneration. Skeletal muscle fibers rely on a proper con-
nection with matrix to transduce muscle tension and to
maintain cell integrity. Endomysial deposition of ahnak1
could influence these processes. A barrier function for
ahnak expressing cells has been described after spinal cord
injury and at the blood brain barrier (Salim et al. 2009;
Gentil et al. 2005; von Boxberg et al. 2006). A similar
effect might be mediated by the ahnak1 positive line
structures partially ensheathing dystrophic muscle fibers.
Therefore we suggest that ahnak1 deposition outside the
Fig. 7 Ahnak1 and annexin2 are present in vesicles secreted from
human myotubes. a Myotubes were incubated with 0.5 lM PMA,
1 lM ionomycin (Iono), or vehicle as control (Con) for 10 min.
Ahnak1 and annexin2 are present in vesicles secreted by ionomycin
treatment (left panel). The corresponding myotubes express ahnak1,
annexin2 and desmin (right panel) as assessed by Western blotting.
b Electron micrographs of secreted vesicles purified from ionomycin
treated myotubes. Representative images show rounded vesicles of
150–200 nm in diameter (bar, 500 nm)
Table 1 Size distribution of vesicles secreted from human myotubes
Preparation Filter Vesicles
counted
Mean
diameter (nm)
Standard
deviation (nm)
1 No 119 178.6 56.7
2 No 206 211.8 60.4
3 Yes 154 147.9 54.8
4 Yes 185 154.2 54.9
Vesicles were released from human myotubes by ionomycin treat-
ment (1 lM, 10 min), separated by differential centrifugation and
analyzed by electron microscopy. Size distribution did not differ with
or without filtration through a 0.22 lm filter
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muscle fiber may contribute to impaired muscle function in
LGMD patients.
An interesting question arising from the present study is
the localization of ahnak1 in other muscular dystrophies.
We studied patients with Becker muscular dystrophy but
our material was limited to two muscle biopsy specimens.
Our preliminary data reveal aberrant ahnak1 localization in
the endomysium in these two patients. This may indicate
that extracellular ahnak1 might be a more general phe-
nomenon in muscular dystrophies and is a subject of our
ongoing research.
Another important finding of our study is the identifi-
cation of ahnak1 in small vesicles (*150 nm) secreted
from myotubes after treatment with ionomycin to induce
Ca2? rise. This resembles the process of Ca2? induced
release of enlargeosomes which are non-secretory, cyto-
plasmic organelles competent for regulated exocytosis.
Enlargeosomes participate in plasma membrane enlarge-
ment and repair and contain ahnak1 and annexin 2 as
marker proteins (Borgonovo et al. 2002). Ahnak1-rich
membranes derived from enlargeosome exocytosis undergo
either endocytosis or release in shedding vesicles (Cocucci
et al. 2007, 2009; Lorusso et al. 2006). In general, vesicle
release into the extracellular environment represents a way
for discarding proteins and membrane but also for inter-
cellular communication through the transfer of proteins,
RNA, and miRNA (Cocucci et al. 2009). Shedded vesicles
can also serve as diagnostic markers. Very recently, ah-
nak1-containing vesicles have been detected in the sera of
patients with pancreatic cancer (Uozumi et al. 2010). To
our knowledge here we demonstrate for the first time the
release of ahnak1-containing vesicles from differentiated
human myotubes. Thus, endomysial ahnak1 may originate
from skeletal muscle cells in muscular dystrophies fol-
lowing repeated cycles of degeneration and regeneration.
However, other sources of endomysial ahnak1 remain to be
investigated. We can not exclude that it originates from
other cell types like fibroblasts, immune, endothelial, or
smooth muscle cells or could simply represent cellular
remnants.
In summary, the pivotal finding in our study is the
identification of ahnak1 as novel constituent of endomysial
connective tissue in patients with calpainopathy
(LGMD2A) and dysferlinopathy (LGMD2B), two geneti-
cally distinct muscular dystrophies. We demonstrate for the
first time the release of ahnak1-containing vesicles from
myotubes that may be one mechanism underlying ahnak1
mislocalization. The perspectives of our study lie in
unravelling the mechanisms of ahnak1 displacement and its
contribution to impaired muscle function.
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Online Resource 1 Localization of ahnak1 in muscle sections 
Ahnak1 localization was analyzed in sections from 6 healthy controls, 6 patients with dysferlinopathy 
and 6 patients with calpainopathy. After visual inspection, they were grouped into four categories with 
respect to the presence of ahnak1 at the sarcolemma (absent, partially reduced or present) and in the 
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Online Resource 2 Specificity of ahnak immunolabeling 
a Ahnak1 staining in normal human skeletal muscle (upper panel), one patient with dysferlin mutation 
(middle panel) and one patient with calpain3 mutation (lower panel) is blocked by preincubation of the 
antibody with the ahnak1 protein used for immunization. b Ahnak1/2 staining in human skeletal 
muscle assessed by the KIS antibody. Cross-sections of skeletal muscle from a patient with dysferlin 
mutation (middle panel) and a patient with calpain3 mutation (lower panel) demonstrate strong 
dystrophic changes and extracellular ahnak displacement while ahnak staining is regular (upper panel) 
in an exemplary normal healthy human skeletal muscle (bar, 50µm). 
